ID: ALA4110365

Max Phase: Preclinical

Molecular Formula: C9H16N2O3S

Molecular Weight: 232.31

Molecule Type: Small molecule

Representations

Canonical SMILES:  CN(C)C1=N[C@@H]2C[C@H](O)[C@@H](CO)O[C@@H]2S1

Standard InChI:  InChI=1S/C9H16N2O3S/c1-11(2)9-10-5-3-6(13)7(4-12)14-8(5)15-9/h5-8,12-13H,3-4H2,1-2H3/t5-,6+,7-,8-/m1/s1

Standard InChI Key:  AMTGNXFFSFQYJA-ULAWRXDQSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 232.31

Molecular Weight (Monoisotopic): 232.0882

AlogP: -0.51

#Rotatable Bonds: 1

Polar Surface Area: 65.29

Molecular Species: NEUTRAL

HBA: 6

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.94

CX Basic pKa: 8.20

CX LogP: -0.42

CX LogD: -1.27

Aromatic Rings: 0

Heavy Atoms: 15

QED Weighted: 0.64

Np Likeness Score: 0.76

References

1.  (2016)  Selective glycosidase inhibitors and uses thereof, 

2. Selnick HG, Hess JF, Tang C, Liu K, Schachter JB, Ballard JE, Marcus J, Klein DJ, Wang X, Pearson M, Savage MJ, Kaul R, Li TS, Vocadlo DJ, Zhou Y, Zhu Y, Mu C, Wang Y, Wei Z, Bai C, Duffy JL, McEachern EJ..  (2019)  Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies.,  62  (22): [PMID:31487175] [10.1021/acs.jmedchem.9b01090]

Source

Source(2):

• Scientific Literature
• BindingDB Database